Taking Omega-3 Supplements but Levels Stay Low? Your Genes May Be Why.

FADS1 encodes an enzyme called delta-12 desaturase, which catalyzes the first critical step in converting alpha-linolenic acid (ALA), the plant-based omega-3, into EPA and then DHA. This is a rate-limiting step; without efficient FADS1 activity, your body cannot manufacture enough long-chain omega-3s even if you eat flax seeds and walnuts daily.

The rs174537 variant in FADS1, carried by roughly 30-40% of people with European ancestry, significantly reduces desaturase activity. People with this variant convert ALA to EPA at less than half the rate of those with the wild-type allele. Dietary intake of ALA does not compensate; the bottleneck is enzymatic, not caloric.

You experience this as persistently low EPA and DHA despite eating plant-based omega sources or taking ALA supplements. Your omega-3 index stays low. You may also notice slower recovery from inflammation after workouts, delayed wound healing, or persistent joint stiffness that doesn’t respond to standard anti-inflammatory protocols.

BCMO1 encodes the enzyme that converts beta-carotene (from carrots, sweet potato, kale) into retinol, the active form of Vitamin A your cells can actually use. Vitamin A is not incidental to fatty acid metabolism; retinol is required for the expression of genes that encode desaturases and other fatty acid processing enzymes. Without sufficient active Vitamin A, your FADS enzymes may be underexpressed regardless of other factors.

The R267S and A379V variants in BCMO1, present in roughly 45% of the population, reduce conversion efficiency by 50-80%. People carrying these variants who rely on plant-based beta-carotene typically have lower circulating retinol and impaired expression of fatty acid metabolism genes. Your bloodwork might not flag this because serum retinol often appears borderline-normal even when cellular uptake is compromised.

You experience this as persistent difficulty raising omega-3 index despite supplementation, slow recovery from oxidative stress, and sometimes dry skin or slow wound healing that responds poorly to standard interventions.

MTHFR is not a fatty acid gene, but it controls the methylation cycle, the biochemical backbone that allows every nutrient conversion to happen, including the conversion of ALA to EPA and DHA. MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the form of folate your cells use to generate methyl groups. These methyl groups are required by every desaturase enzyme in your body, including FADS1 and FADS2.

The C677T variant in MTHFR, carried by roughly 40% of people with European ancestry, reduces enzyme efficiency by 35-40%. You can have perfectly normal folate intake and still have inadequate methylation capacity, which means your FADS enzymes cannot function optimally even if they are genetically intact. This variant also impairs B12 conversion and methylation-dependent detoxification pathways.

You experience this as stubbornly low omega-3 index even with high ALA and preformed omega supplementation, plus often fatigue, brain fog, or mood changes that standard micronutrient supplementation doesn’t resolve.

VDR encodes the vitamin D receptor, the protein that allows your cells to respond to circulating vitamin D. Vitamin D is not just for bone health; it is a central regulator of gene expression for desaturases, anti-inflammatory pathways, and the immune tolerance that supports healthy inflammation resolution after omega-3 intake. Without efficient VDR signaling, your cells cannot upregulate these genes even if your serum vitamin D is 50 ng/mL.

The FokI polymorphism in VDR, present in roughly 30-50% of the population, produces a shorter or longer form of the receptor with different transcriptional activity. People carrying the longer form require higher vitamin D levels to achieve the same gene expression as those with the shorter form, meaning standard supplementation often leaves you in a functional deficiency state. Serum 25-OH vitamin D may read as adequate while cellular vitamin D signaling remains compromised.

You experience this as persistent low omega-3 index despite adequate supplementation, slow inflammatory recovery, suboptimal immune regulation, and sometimes unresolved fatigue or mood changes that improve only with higher vitamin D doses than standard protocols recommend.

HFE encodes a protein that helps regulate hepcidin, the hormone that controls iron absorption. Iron is a critical cofactor for desaturase enzymes; without adequate iron in the right cellular compartments, FADS1 and FADS2 cannot convert ALA efficiently. HFE variants impact iron bioavailability at the intestinal level, which trickles downstream into impaired desaturase function.

The H63D variant in HFE, present in roughly 15-20% of people with European ancestry, is associated with subtle iron dysregulation. People carrying H63D often have lower circulating iron or impaired iron transport into mitochondria despite adequate dietary intake, which reduces desaturase cofactor availability. Serum ferritin may read as low-normal, masking the functional iron insufficiency affecting your fatty acid metabolism enzymes.

You experience this as persistent low omega-3 index, persistent fatigue despite adequate sleep, and sometimes easy bruising or slow recovery from workouts that responds only to iron supplementation.

FUT2 encodes a fucosyltransferase that determines which sugars are secreted in saliva and mucus. These sugars act as a selective food for specific beneficial bacteria. FUT2 variants change your gut microbiota composition, which directly impacts your capacity to absorb fatty acids and fat-soluble vitamins like vitamins A, D, E, and K. Your microbiota also produces short-chain fatty acids and butyrate, which support intestinal barrier integrity and the anti-inflammatory environment needed for healthy omega-3 status.

The rs602662 variant in FUT2, carried by roughly 50% of the population, is associated with reduced abundance of beneficial Faecalibacterium and other short-chain fatty acid producers. People carrying this variant often have altered microbiota profiles that impair fat-soluble vitamin absorption and reduce the anti-inflammatory capacity that omega-3 supplementation aims to support. You can absorb the omega-3s fine, but the downstream immunological benefit is diminished.

You experience this as low omega-3 index despite supplementation, persistent mild inflammation, occasional bloating or irregular digestion, and inflammatory markers that don’t improve as much as expected after omega-3 supplementation.